Purple Biotech (PPBT) Other Non-Current Liabilities (2019 - 2026)

Purple Biotech (PPBT) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.9 million, up 361.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 361.56% YoY), and the FY2025 annual result was $4.1 million, up 253.87% from the prior year.
• Other Non-Current Liabilities declined to $1.9 million in Q1 2026 per PPBT's latest filing, from $4.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $4.1 million in Q3 2025 and troughed at $267000.0 in Q2 2025.
• A 4-year average of $1.9 million and a median of $1.7 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities tumbled 79.91% in 2025, then surged 361.56% in 2026.
• A 4-year view of Other Non-Current Liabilities shows it stood at $2.5 million in 2023, then plunged by 54.37% to $1.1 million in 2024, then jumped by 253.87% to $4.1 million in 2025, then tumbled by 53.34% to $1.9 million in 2026.
• Business Quant data shows PPBT's Other Non-Current Liabilities at $1.9 million in Q1 2026, $4.1 million in Q4 2025, and $4.1 million in Q3 2025.